Oncopeptidomics - A commentary on opportunities and limitations

Cancer Letters

Volumn 249, Issue 1, 2007, Pages 80-86

  Tammen, Harald ^a   Zucht, Hans Dieter ^a   Budde, Petra ^a  

^a Digilab BioVisioN GmbH   (Germany)

Author keywords

Biomarker; Cancer; Discovery; Peptidomics; Protease; Validation

Indexed keywords

BIOLOGICAL MARKER; PEPTIDE; TUMOR MARKER;

CARCINOGENESIS; GENE EXPRESSION PROFILING; MASS SPECTROMETRY; MOLECULAR WEIGHT; ONCOLOGY; PEPTIDOMICS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 33947272665     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.12.019     Document Type: Review

References (63)

1. Naylor S. Biomarkers: current perspectives and future prospects. Expert. Rev. Mol. Diagn. 3 (2003) 525-529
2. Rawlings N.D., Morton F.R., and Barrett A.J. MEROPS: the peptidase database. Nucleic Acids Res. 34 (2006) D270-D272
3. Rubin H. Complementary approaches to understanding the role of proteases and their natural inhibitors in neoplastic development: retrospect and prospect. Carcinogenesis 24 (2003) 803-816
4. Rubin H. Systemic effects of cancer: role of multiple proteases and their toxic peptide products. Med. Sci. Monit. 11 (2005) RA221-RA228
5. Overall C.M., and Dean R.A. Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev. 25 (2006) 69-75
6. Paliouras M., and Diamandis E.P. The kallikrein world: an update on the human tissue kallikreins. Biol. Chem. 387 (2006) 643-652
7. Journet A., and Ferro M. The potentials of MS-based subproteomic approaches in medical science: the case of lysosomes and breast cancer. Mass. Spectrom. Rev. 23 (2004) 393-442
8. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., and Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 (1995) 3752-3756
9. Dellian M., Yuan F., Trubetskoy V.S., Torchilin V.P., and Jain R.K. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br. J. Cancer 82 (2000) 1513-1518
10. Carlsson S. Fibrinogen degradation products in serum from patients with cancer. Acta Chir. Scand. 139 (1973) 499-502
11. Unkeless J., Dano K., Kellerman G.M., and Reich E. Fibrinolysis associated with oncogenic transformation. Partial purification characterization of the cell factor a plasminogen activator. J. Biol. Chem. 249 (1974) 4295-4305
12. Vierhapper H., Niederle B., Bieglmayer C., Kaserer K., and Baumgartner-Parzer S. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 15 (2005) 1267-1272
13. Schrader M., and Schulz-Knappe P. Peptidomics technologies for human body fluids. Trends Biotechnol. 19 (2001) 55-60
14. Baggerman G., Verleyen P., Clynen E., Huybrechts J., De Loof A., and Schoofs L. Peptidomics. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 803 (2004) 3-16
15. Soloviev M., and Finch P. Peptidomics current status. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 815 (2005) 11-24
16. Soloviev M., and Finch P. Peptidomics: bridging the gap between proteome and metabolome. Proteomics 6 (2006) 744-747
17. Richter R., Schulz-Knappe P., Schrader M., Standker L., Jurgens M., Tammen H., and Forssmann W.G. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J. Chromatogr. B: Biomed. Sci. Appl. 726 (1999) 25-35
18. Schulz-Knappe P., Zucht H.D., Heine G., Jurgens M., Hess R., and Schrader M. Peptidomics: the comprehensive analysis of peptides in complex biological mixtures. Comb. Chem. High Throughput Screen. 4 (2001) 207-217
19. Palagi P.M., Walther D., Quadroni M., Catherinet S., Burgess J., Zimmermann-Ivol C.G., Sanchez J.C., Binz P.A., Hochstrasser D.F., and Appel R.D. MSight: an image analysis software for liquid chromatography-mass spectrometry. Proteomics 5 (2005) 2381-2384
20. Zucht H.D., Lamerz J., Khamenia V., Appel A., Tammen H., Crameri R., and Selle H. Datamining Methodology for LC-MALDI-MS Based Peptide Profiling. Comb. Chem. High Throughput Screen. 8 (2005) 717-723
21. Pierson J., Norris J.L., Aerni H.R., Svenningsson P., Caprioli R.M., and Andren P.E. Molecular profiling of experimental Parkinson's disease: direct analysis of peptides and proteins on brain tissue sections by MALDI mass spectrometry. J. Proteome. Res. 3 (2004) 289-295
22. Jurgens M., Appel A., Heine G., Neitz S., Menzel C., Tammen H., and Zucht H.D. Towards characterization of the human urinary peptidome. Comb. Chem. High Throughput Screen. 8 (2005) 757-765
23. Pasinetti G.M., Ungar L.H., Lange D.J., Yemul S., Deng H., Yuan X., Brown R.H., Cudkowicz M.E., Newhall K., Peskind E., Marcus S., and Ho L. Identification of potential CSF biomarkers in ALS. Neurology 66 (2006) 1218-1222
24. Sasaki K., Sato K., Akiyama Y., Yanagihara K., Oka M., and Yamaguchi K. Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. Cancer Res. 62 (2002) 4894-4898
25. Qian W.J., Jacobs J.M., Liu T., Camp D.G., and Smith R.D. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol. Cell. Proteomics 5 (2006) 1727-1744
26. Diamandis E.P. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl. Cancer Inst. 96 (2004) 353-356
27. Anderson N.L., and Anderson N.G. The human plasma proteome: history character and diagnostic prospects. Mol. Cell. Proteomics 1 (2002) 845-867
28. Anderson N.L., Polanski M., Pieper E., Gatlin T., Tirumalai R.S., Conrads T.P., Veenstra T.D., Atkins J.N., Pound J.G., Fagan R., and Lobley A. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell. Proteomics 3 (2004) 311-326
29. Omenn G.S. The Human Proteome Organization Plasma Proteome Project pilot phase: reference specimens technology platform comparisons and standardized data submissions and analyses. Proteomics 4 (2004) 1235-1240
30. Tammen H., Schulte I., Hess R., Menzel C., Kellmann M., Mohring T., and Schulz-Knappe P. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 5 (2005) 3414-3422
31. Petricoin E.F., Mills G.B., Kohn E.C., and Liotta L.A. Proteomic patterns in serum and identification of ovarian cancer. Lancet 360 (2002) 170-171
32. Diamandis E.P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol. Cell. Proteomics 3 (2004) 367-378
33. Vitzthum F., Behrens F., Anderson N.L., and Shaw J.H. Proteomics: from basic research to diagnostic application. A review of requirements needs. J. Proteome Res. 4 (2005) 1086-1097
34. Le L., Chi K., Tyldesley S., Flibotte S., Diamond D.L., Kuzyk M.A., and Sadar M.D. Identification of serum Amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin. Chem. 51 (2005) 695-707
35. Villanueva J., Martorella A.J., Lawlor K., Philip J., Fleisher M., Robbins R.J., and Tempst P. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol. Cell. Proteomics 5 (2006) 1840-1852
36. Ye B., Cramer D.W., Skates S.J., Gygi S.P., Pratomo V., Fu L., Horick N.K., Licklider L.J., Schorge J.O., Berkowitz R.S., and Mok S.C. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 9 (2003) 2904-2911
37. Malik G., Ward M.D., Gupta S.K., Trosset M.W., Grizzle W.E., Adam B.L., Diaz J.I., and Semmes O.J. Serum levels of an isoform of Apolipoprotein A-II as a potential marker for prostate cancer. Clin. Cancer Res. 11 (2005) 1073-1085
38. Hortin G.L. The maldi-tof mass spectrometric view of the plasma proteome and peptidome. Clin. Chem. 52 (2006) 1223-1237
39. Koomen J.M., Shih L.N., Coombes K.R., Li D., Xiao L.C., Fidler I.J., Abbruzzese J.L., and Kobayashi R. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin. Cancer Res. 11 (2005) 1110-1118
40. Villanueva J., Shaffer D.R., Philip J., Chaparro C.A., Erdjument-Bromage H., Olshen A.B., Fleisher M., Lilja H., Brogi E., Boyd J., Sanchez-Carbayo M., Holland E.C., Cordon-Cardo C., Scher H.I., and Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116 (2006) 271-284
41. Liotta L.A., and Petricoin E.F. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J. Clin. Invest. 116 (2006) 26-30
42. Besada V., Diaz M., Becker M., Ramos Y., Castellanos-Serra L., and Fichtner I. Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance. Proteomics 6 (2006) 1038-1048
43. Tammen H., Schorn K., Selle H., Hess R., Neitz S., Reiter R., and Schulz-Knappe P. Identification of Peptide tumor markers in a tumor graft model in immunodeficient mice. Comb. Chem. High Throughput Screen. 8 (2005) 783-788
44. Semmes O.J., Malik G., and Ward M. Application of mass spectrometry to the discovery of biomarkers for detection of prostate cancer. J. Cell. Biochem. 98 (2006) 496-503
45. Ricolleau G., Charbonnel C., Lode L., Loussouarn D., Joalland M.P., Bogumil R., Jourdain S., Minvielle S., Campone M., Deporte-Fety R., Campion L., and Jezequel P. Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics 6 (2006) 1963-1975
46. Traub F., Jost M., Hess R., Schorn K., Menzel C., Budde P., Schulz-Knappe P., Lamping N., Pich A., Kreipe H., and Tammen H. Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas. Lab. Invest. 86 (2006) 246-253
47. Schmitt M., Harbeck N., Daidone M.G., Brynner N., Duffy M.J., Foekens J.A., and Sweep F.C. Identification validation clinical implementation of tumor-associated biomarkers to improve therapy concepts survival and quality of life of cancer patients: tasks of the receptor and biomarker group of the European organization for research and treatment of cancer. Int. J. Oncol. 25 (2004) 1397-1406
48. Zolg J.W., and Langen H. How industry is approaching the search for new diagnostic markers and biomarkers. Mol. Cell. Proteomics. 3 (2004) 345-354
49. J.C. Libeer, Validation of clinical laboratory results: discussion of essential validation elements, Drug Info. J. 31 (97 A.D.) 243-250.
50. Chambers A.F., and Vanderhyden B.C. Ovarian cancer biomarkers in urine. Clin. Cancer Res. 12 (2006) 323-327
51. Diamandis E.P. Peptidomics for cancer diagnosis: present and future. J. Proteome Res. 5 (2006) 2079-2082
52. Schrader M., and Selle H. The process chain for peptidomic biomarker discovery. Dis. Markers 22 (2006) 235-245
53. Zolg W. The proteomics search for diagnostic bionmarkers: lost in translation?. Mol Cell. Proteomics 5 (2006) 1720-1726
54. Klimentzou P., Paravatou-Petsotas M., Zikos C., Beck A., Skopeliti M., Czarnecki J., Tsitsilonis O., Voelter W., Livaniou E., and Evangelatos G.P. Development and immunochemical evaluation of antibodies Y for the poorly immunogenic polypeptide prothymosin alpha. Peptides 27 (2006) 183-193
55. Kinter M. Toward broader inclusion of liquid chromatography-mass spectrometry in the clinical laboratory. Clin. Chem. 50 (2004) 1500-1502
56. Sen J.W., Bergen III H.R., and Heegaard N.H. On-line immunoaffinity-liquid chromatography-mass spectrometry for identification of amyloid disease markers in biological fluids. Anal. Chem. 75 (2003) 1196-1202
57. Corlin D.B., Sen J.W., Ladefoged S., Lund G.B., Nissen M.H., and Heegaard N.H. Quantification of cleaved beta2-microglobulin in serum from patients undergoing chronic hemodialysis. Clin. Chem. 51 (2005) 1177-1184
58. Hayes D.F., Bast R.C., Desch C.E., Fritsche Jr. H., Kemeny N.E., Jessup J.M., Locker G.Y., Macdonald J.S., Mennel R.G., Norton L., Ravdin P., Taube S., and Winn R.J. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl. Cancer Inst. 88 (1996) 1456-1466
59. Schmitt M., Harbeck N., Daidone M.G., Brynner N., Duffy M.J., Foekens J.A., and Sweep F.C. Identification validation clinical implementation of tumor-associated biomarkers to improve therapy concepts survival and quality of life of cancer patients: tasks of the receptor and biomarker group of the European organization for research and treatment of cancer. Int. J. Oncol. 25 (2004) 1397-1406
60. Hertig A.T. Human trophoblast: normal abnormal. A plea for the study of the normal so as to understand the abnormal. Ward Burdick Award Address. Am. J. Clin. Pathol. 47 (1967) 249-268
61. Nery R. Carcinogenic mechanisms: a critical review and a suggestion that oncogenesis may be adaptive ontogenesis. Chem. Biol. Interact. 12 (1976) 145-169
62. Manzo G. Phylogenesis-ontogenesis-oncogenesis. Med. Hypotheses 30 (1989) 245-257
63. Phillips K.A., Van Bebber S., and Issa A.M. Diagnostics and biomarker development: priming the pipeline. Nat. Rev. Drug Discov. 5 (2006) 463-469